nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP2D6—Gefitinib—lung cancer	0.0754	0.125	CbGbCtD
Vilazodone—CYP2D6—Vinorelbine—lung cancer	0.0581	0.096	CbGbCtD
Vilazodone—CYP3A4—Topotecan—lung cancer	0.0524	0.0867	CbGbCtD
Vilazodone—CYP3A4—Gefitinib—lung cancer	0.048	0.0793	CbGbCtD
Vilazodone—CYP3A4—Teniposide—lung cancer	0.0465	0.0769	CbGbCtD
Vilazodone—CYP2D6—Erlotinib—lung cancer	0.0446	0.0737	CbGbCtD
Vilazodone—CYP3A4—Vinorelbine—lung cancer	0.0369	0.0611	CbGbCtD
Vilazodone—CYP2D6—Vinblastine—lung cancer	0.0358	0.0592	CbGbCtD
Vilazodone—CYP3A4—Crizotinib—lung cancer	0.0294	0.0486	CbGbCtD
Vilazodone—CYP3A4—Erlotinib—lung cancer	0.0284	0.0469	CbGbCtD
Vilazodone—CYP3A4—Paclitaxel—lung cancer	0.026	0.0429	CbGbCtD
Vilazodone—CYP3A4—Irinotecan—lung cancer	0.0256	0.0423	CbGbCtD
Vilazodone—CYP3A4—Vinblastine—lung cancer	0.0228	0.0376	CbGbCtD
Vilazodone—CYP2D6—Doxorubicin—lung cancer	0.022	0.0364	CbGbCtD
Vilazodone—CYP3A4—Etoposide—lung cancer	0.0205	0.0339	CbGbCtD
Vilazodone—CYP3A4—Docetaxel—lung cancer	0.0188	0.031	CbGbCtD
Vilazodone—CYP3A4—Doxorubicin—lung cancer	0.014	0.0231	CbGbCtD
Vilazodone—Cardiac disorder—Irinotecan—lung cancer	0.00077	0.00338	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Topotecan—lung cancer	0.000761	0.00334	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Erlotinib—lung cancer	0.000753	0.0033	CcSEcCtD
Vilazodone—Paraesthesia—Topotecan—lung cancer	0.00075	0.00329	CcSEcCtD
Vilazodone—Cardiac disorder—Gemcitabine—lung cancer	0.00075	0.00329	CcSEcCtD
Vilazodone—Breast disorder—Docetaxel—lung cancer	0.000749	0.00329	CcSEcCtD
Vilazodone—Insomnia—Erlotinib—lung cancer	0.000748	0.00328	CcSEcCtD
Vilazodone—Decreased appetite—Vinblastine—lung cancer	0.000748	0.00328	CcSEcCtD
Vilazodone—Arthralgia—Vinorelbine—lung cancer	0.000746	0.00327	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.00074	0.00325	CcSEcCtD
Vilazodone—Connective tissue disorder—Cisplatin—lung cancer	0.00074	0.00325	CcSEcCtD
Vilazodone—Dyspepsia—Topotecan—lung cancer	0.000735	0.00323	CcSEcCtD
Vilazodone—Dyspepsia—Erlotinib—lung cancer	0.000728	0.00319	CcSEcCtD
Vilazodone—Decreased appetite—Topotecan—lung cancer	0.000726	0.00319	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Topotecan—lung cancer	0.000721	0.00316	CcSEcCtD
Vilazodone—Fatigue—Topotecan—lung cancer	0.00072	0.00316	CcSEcCtD
Vilazodone—Decreased appetite—Erlotinib—lung cancer	0.000719	0.00315	CcSEcCtD
Vilazodone—Vomiting—Teniposide—lung cancer	0.000717	0.00314	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Erlotinib—lung cancer	0.000714	0.00313	CcSEcCtD
Vilazodone—Fatigue—Erlotinib—lung cancer	0.000713	0.00313	CcSEcCtD
Vilazodone—Flatulence—Irinotecan—lung cancer	0.000712	0.00312	CcSEcCtD
Vilazodone—Feeling abnormal—Vinblastine—lung cancer	0.000709	0.00311	CcSEcCtD
Vilazodone—Abnormal dreams—Doxorubicin—lung cancer	0.000704	0.00309	CcSEcCtD
Vilazodone—Eye disorder—Cisplatin—lung cancer	0.000704	0.00309	CcSEcCtD
Vilazodone—Nervous system disorder—Vinorelbine—lung cancer	0.000701	0.00307	CcSEcCtD
Vilazodone—Cardiac disorder—Cisplatin—lung cancer	0.000699	0.00307	CcSEcCtD
Vilazodone—Skin disorder—Vinorelbine—lung cancer	0.000694	0.00304	CcSEcCtD
Vilazodone—Feeling abnormal—Topotecan—lung cancer	0.000688	0.00302	CcSEcCtD
Vilazodone—Nausea—Teniposide—lung cancer	0.00067	0.00294	CcSEcCtD
Vilazodone—Connective tissue disorder—Paclitaxel—lung cancer	0.000665	0.00292	CcSEcCtD
Vilazodone—Dry eye—Doxorubicin—lung cancer	0.000658	0.00289	CcSEcCtD
Vilazodone—Malnutrition—Cisplatin—lung cancer	0.000656	0.00288	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Vinorelbine—lung cancer	0.000651	0.00286	CcSEcCtD
Vilazodone—Flatulence—Cisplatin—lung cancer	0.000646	0.00283	CcSEcCtD
Vilazodone—Eye disorder—Etoposide—lung cancer	0.000645	0.00283	CcSEcCtD
Vilazodone—Paraesthesia—Vinorelbine—lung cancer	0.000642	0.00281	CcSEcCtD
Vilazodone—Cardiac disorder—Etoposide—lung cancer	0.00064	0.00281	CcSEcCtD
Vilazodone—Eye disorder—Paclitaxel—lung cancer	0.000632	0.00277	CcSEcCtD
Vilazodone—Cardiac disorder—Paclitaxel—lung cancer	0.000628	0.00275	CcSEcCtD
Vilazodone—Decreased appetite—Vinorelbine—lung cancer	0.000621	0.00272	CcSEcCtD
Vilazodone—Vision blurred—Cisplatin—lung cancer	0.000618	0.00271	CcSEcCtD
Vilazodone—Asthenia—Vinblastine—lung cancer	0.000617	0.00271	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000617	0.00271	CcSEcCtD
Vilazodone—Fatigue—Vinorelbine—lung cancer	0.000616	0.0027	CcSEcCtD
Vilazodone—Tremor—Cisplatin—lung cancer	0.000614	0.00269	CcSEcCtD
Vilazodone—Asthenia—Topotecan—lung cancer	0.000599	0.00263	CcSEcCtD
Vilazodone—Arthralgia—Gemcitabine—lung cancer	0.000599	0.00263	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000595	0.00261	CcSEcCtD
Vilazodone—Asthenia—Erlotinib—lung cancer	0.000593	0.0026	CcSEcCtD
Vilazodone—Mental disorder—Paclitaxel—lung cancer	0.000593	0.0026	CcSEcCtD
Vilazodone—Malnutrition—Paclitaxel—lung cancer	0.000589	0.00258	CcSEcCtD
Vilazodone—Feeling abnormal—Vinorelbine—lung cancer	0.000589	0.00258	CcSEcCtD
Vilazodone—Diarrhoea—Vinblastine—lung cancer	0.000588	0.00258	CcSEcCtD
Vilazodone—Dysgeusia—Etoposide—lung cancer	0.000588	0.00258	CcSEcCtD
Vilazodone—Flatulence—Paclitaxel—lung cancer	0.00058	0.00255	CcSEcCtD
Vilazodone—Nervous system disorder—Irinotecan—lung cancer	0.000578	0.00254	CcSEcCtD
Vilazodone—Dysgeusia—Paclitaxel—lung cancer	0.000577	0.00253	CcSEcCtD
Vilazodone—Nervousness—Paclitaxel—lung cancer	0.000572	0.00251	CcSEcCtD
Vilazodone—Diarrhoea—Topotecan—lung cancer	0.000572	0.00251	CcSEcCtD
Vilazodone—Irritability—Methotrexate—lung cancer	0.00057	0.0025	CcSEcCtD
Vilazodone—Hyperhidrosis—Irinotecan—lung cancer	0.00057	0.0025	CcSEcCtD
Vilazodone—Dizziness—Vinblastine—lung cancer	0.000569	0.00249	CcSEcCtD
Vilazodone—Convulsion—Cisplatin—lung cancer	0.000568	0.00249	CcSEcCtD
Vilazodone—Diarrhoea—Erlotinib—lung cancer	0.000566	0.00248	CcSEcCtD
Vilazodone—Connective tissue disorder—Docetaxel—lung cancer	0.000564	0.00247	CcSEcCtD
Vilazodone—Nervous system disorder—Gemcitabine—lung cancer	0.000563	0.00247	CcSEcCtD
Vilazodone—Skin disorder—Gemcitabine—lung cancer	0.000558	0.00245	CcSEcCtD
Vilazodone—Vision blurred—Paclitaxel—lung cancer	0.000555	0.00243	CcSEcCtD
Vilazodone—Hyperhidrosis—Gemcitabine—lung cancer	0.000555	0.00243	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000554	0.00243	CcSEcCtD
Vilazodone—Dizziness—Topotecan—lung cancer	0.000552	0.00242	CcSEcCtD
Vilazodone—Tremor—Paclitaxel—lung cancer	0.000552	0.00242	CcSEcCtD
Vilazodone—Increased appetite—Doxorubicin—lung cancer	0.000551	0.00242	CcSEcCtD
Vilazodone—Vomiting—Vinblastine—lung cancer	0.000547	0.0024	CcSEcCtD
Vilazodone—Dizziness—Erlotinib—lung cancer	0.000547	0.0024	CcSEcCtD
Vilazodone—Agitation—Paclitaxel—lung cancer	0.000541	0.00237	CcSEcCtD
Vilazodone—Breast disorder—Methotrexate—lung cancer	0.00054	0.00237	CcSEcCtD
Vilazodone—Eye disorder—Docetaxel—lung cancer	0.000536	0.00235	CcSEcCtD
Vilazodone—Insomnia—Irinotecan—lung cancer	0.000533	0.00234	CcSEcCtD
Vilazodone—Cardiac disorder—Docetaxel—lung cancer	0.000532	0.00233	CcSEcCtD
Vilazodone—Vomiting—Topotecan—lung cancer	0.000531	0.00233	CcSEcCtD
Vilazodone—Paraesthesia—Irinotecan—lung cancer	0.000529	0.00232	CcSEcCtD
Vilazodone—Vomiting—Erlotinib—lung cancer	0.000526	0.0023	CcSEcCtD
Vilazodone—Nervous system disorder—Cisplatin—lung cancer	0.000525	0.0023	CcSEcCtD
Vilazodone—Somnolence—Irinotecan—lung cancer	0.000524	0.0023	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000523	0.00229	CcSEcCtD
Vilazodone—Palpitations—Paclitaxel—lung cancer	0.000521	0.00228	CcSEcCtD
Vilazodone—Convulsion—Etoposide—lung cancer	0.00052	0.00228	CcSEcCtD
Vilazodone—Skin disorder—Cisplatin—lung cancer	0.00052	0.00228	CcSEcCtD
Vilazodone—Hyponatraemia—Doxorubicin—lung cancer	0.000519	0.00228	CcSEcCtD
Vilazodone—Insomnia—Gemcitabine—lung cancer	0.000519	0.00228	CcSEcCtD
Vilazodone—Dyspepsia—Irinotecan—lung cancer	0.000519	0.00228	CcSEcCtD
Vilazodone—Hyperhidrosis—Cisplatin—lung cancer	0.000517	0.00227	CcSEcCtD
Vilazodone—Paraesthesia—Gemcitabine—lung cancer	0.000516	0.00226	CcSEcCtD
Vilazodone—Asthenia—Vinorelbine—lung cancer	0.000513	0.00225	CcSEcCtD
Vilazodone—Decreased appetite—Irinotecan—lung cancer	0.000512	0.00225	CcSEcCtD
Vilazodone—Nausea—Vinblastine—lung cancer	0.000511	0.00224	CcSEcCtD
Vilazodone—Somnolence—Gemcitabine—lung cancer	0.00051	0.00224	CcSEcCtD
Vilazodone—Convulsion—Paclitaxel—lung cancer	0.00051	0.00224	CcSEcCtD
Vilazodone—Migraine—Doxorubicin—lung cancer	0.000509	0.00223	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Irinotecan—lung cancer	0.000509	0.00223	CcSEcCtD
Vilazodone—Fatigue—Irinotecan—lung cancer	0.000508	0.00223	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000508	0.00223	CcSEcCtD
Vilazodone—Mental disorder—Docetaxel—lung cancer	0.000502	0.0022	CcSEcCtD
Vilazodone—Arthralgia—Paclitaxel—lung cancer	0.000501	0.0022	CcSEcCtD
Vilazodone—Malnutrition—Docetaxel—lung cancer	0.000499	0.00219	CcSEcCtD
Vilazodone—Decreased appetite—Gemcitabine—lung cancer	0.000499	0.00219	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000498	0.00218	CcSEcCtD
Vilazodone—Nausea—Topotecan—lung cancer	0.000496	0.00218	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000496	0.00217	CcSEcCtD
Vilazodone—Fatigue—Gemcitabine—lung cancer	0.000495	0.00217	CcSEcCtD
Vilazodone—Nausea—Erlotinib—lung cancer	0.000491	0.00215	CcSEcCtD
Vilazodone—Dry mouth—Paclitaxel—lung cancer	0.00049	0.00215	CcSEcCtD
Vilazodone—Diarrhoea—Vinorelbine—lung cancer	0.000489	0.00214	CcSEcCtD
Vilazodone—Dysgeusia—Docetaxel—lung cancer	0.000489	0.00214	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000488	0.00214	CcSEcCtD
Vilazodone—Feeling abnormal—Irinotecan—lung cancer	0.000486	0.00213	CcSEcCtD
Vilazodone—Paraesthesia—Cisplatin—lung cancer	0.000481	0.00211	CcSEcCtD
Vilazodone—Skin disorder—Etoposide—lung cancer	0.000476	0.00209	CcSEcCtD
Vilazodone—Erectile dysfunction—Methotrexate—lung cancer	0.000476	0.00209	CcSEcCtD
Vilazodone—Hyperhidrosis—Etoposide—lung cancer	0.000474	0.00208	CcSEcCtD
Vilazodone—Feeling abnormal—Gemcitabine—lung cancer	0.000473	0.00208	CcSEcCtD
Vilazodone—Dizziness—Vinorelbine—lung cancer	0.000473	0.00207	CcSEcCtD
Vilazodone—Nervous system disorder—Paclitaxel—lung cancer	0.000471	0.00207	CcSEcCtD
Vilazodone—Breast disorder—Doxorubicin—lung cancer	0.000468	0.00205	CcSEcCtD
Vilazodone—Skin disorder—Paclitaxel—lung cancer	0.000467	0.00205	CcSEcCtD
Vilazodone—Decreased appetite—Cisplatin—lung cancer	0.000465	0.00204	CcSEcCtD
Vilazodone—Hyperhidrosis—Paclitaxel—lung cancer	0.000465	0.00204	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Cisplatin—lung cancer	0.000462	0.00203	CcSEcCtD
Vilazodone—Vomiting—Vinorelbine—lung cancer	0.000454	0.00199	CcSEcCtD
Vilazodone—Palpitations—Docetaxel—lung cancer	0.000441	0.00193	CcSEcCtD
Vilazodone—Feeling abnormal—Cisplatin—lung cancer	0.000441	0.00193	CcSEcCtD
Vilazodone—Paraesthesia—Etoposide—lung cancer	0.00044	0.00193	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000438	0.00192	CcSEcCtD
Vilazodone—Somnolence—Etoposide—lung cancer	0.000436	0.00191	CcSEcCtD
Vilazodone—Insomnia—Paclitaxel—lung cancer	0.000435	0.00191	CcSEcCtD
Vilazodone—Convulsion—Docetaxel—lung cancer	0.000433	0.0019	CcSEcCtD
Vilazodone—Paraesthesia—Paclitaxel—lung cancer	0.000432	0.00189	CcSEcCtD
Vilazodone—Somnolence—Paclitaxel—lung cancer	0.000427	0.00187	CcSEcCtD
Vilazodone—Decreased appetite—Etoposide—lung cancer	0.000426	0.00187	CcSEcCtD
Vilazodone—Arthralgia—Docetaxel—lung cancer	0.000425	0.00186	CcSEcCtD
Vilazodone—Nausea—Vinorelbine—lung cancer	0.000425	0.00186	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Etoposide—lung cancer	0.000423	0.00186	CcSEcCtD
Vilazodone—Dyspepsia—Paclitaxel—lung cancer	0.000423	0.00186	CcSEcCtD
Vilazodone—Asthenia—Irinotecan—lung cancer	0.000423	0.00185	CcSEcCtD
Vilazodone—Fatigue—Etoposide—lung cancer	0.000423	0.00185	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000422	0.00185	CcSEcCtD
Vilazodone—Decreased appetite—Paclitaxel—lung cancer	0.000418	0.00183	CcSEcCtD
Vilazodone—Dry mouth—Docetaxel—lung cancer	0.000416	0.00182	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000415	0.00182	CcSEcCtD
Vilazodone—Fatigue—Paclitaxel—lung cancer	0.000414	0.00182	CcSEcCtD
Vilazodone—Pollakiuria—Doxorubicin—lung cancer	0.000413	0.00181	CcSEcCtD
Vilazodone—Asthenia—Gemcitabine—lung cancer	0.000412	0.00181	CcSEcCtD
Vilazodone—Feeling abnormal—Etoposide—lung cancer	0.000404	0.00177	CcSEcCtD
Vilazodone—Diarrhoea—Irinotecan—lung cancer	0.000403	0.00177	CcSEcCtD
Vilazodone—Nervous system disorder—Docetaxel—lung cancer	0.0004	0.00175	CcSEcCtD
Vilazodone—Feeling abnormal—Paclitaxel—lung cancer	0.000396	0.00174	CcSEcCtD
Vilazodone—Skin disorder—Docetaxel—lung cancer	0.000396	0.00174	CcSEcCtD
Vilazodone—Diarrhoea—Gemcitabine—lung cancer	0.000393	0.00172	CcSEcCtD
Vilazodone—Dizziness—Irinotecan—lung cancer	0.00039	0.00171	CcSEcCtD
Vilazodone—Eye disorder—Methotrexate—lung cancer	0.000386	0.00169	CcSEcCtD
Vilazodone—Asthenia—Cisplatin—lung cancer	0.000384	0.00168	CcSEcCtD
Vilazodone—Cardiac disorder—Methotrexate—lung cancer	0.000384	0.00168	CcSEcCtD
Vilazodone—Vomiting—Irinotecan—lung cancer	0.000375	0.00164	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000371	0.00163	CcSEcCtD
Vilazodone—Insomnia—Docetaxel—lung cancer	0.000369	0.00162	CcSEcCtD
Vilazodone—Diarrhoea—Cisplatin—lung cancer	0.000366	0.00161	CcSEcCtD
Vilazodone—Paraesthesia—Docetaxel—lung cancer	0.000366	0.0016	CcSEcCtD
Vilazodone—Vomiting—Gemcitabine—lung cancer	0.000365	0.0016	CcSEcCtD
Vilazodone—Somnolence—Docetaxel—lung cancer	0.000362	0.00159	CcSEcCtD
Vilazodone—Mental disorder—Methotrexate—lung cancer	0.000362	0.00159	CcSEcCtD
Vilazodone—Malnutrition—Methotrexate—lung cancer	0.00036	0.00158	CcSEcCtD
Vilazodone—Dyspepsia—Docetaxel—lung cancer	0.000359	0.00157	CcSEcCtD
Vilazodone—Decreased appetite—Docetaxel—lung cancer	0.000354	0.00155	CcSEcCtD
Vilazodone—Dysgeusia—Methotrexate—lung cancer	0.000352	0.00155	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Docetaxel—lung cancer	0.000352	0.00154	CcSEcCtD
Vilazodone—Asthenia—Etoposide—lung cancer	0.000352	0.00154	CcSEcCtD
Vilazodone—Connective tissue disorder—Doxorubicin—lung cancer	0.000352	0.00154	CcSEcCtD
Vilazodone—Fatigue—Docetaxel—lung cancer	0.000351	0.00154	CcSEcCtD
Vilazodone—Nausea—Irinotecan—lung cancer	0.00035	0.00154	CcSEcCtD
Vilazodone—Asthenia—Paclitaxel—lung cancer	0.000345	0.00151	CcSEcCtD
Vilazodone—Nausea—Gemcitabine—lung cancer	0.000341	0.0015	CcSEcCtD
Vilazodone—Vomiting—Cisplatin—lung cancer	0.00034	0.00149	CcSEcCtD
Vilazodone—Vision blurred—Methotrexate—lung cancer	0.000339	0.00149	CcSEcCtD
Vilazodone—Feeling abnormal—Docetaxel—lung cancer	0.000336	0.00147	CcSEcCtD
Vilazodone—Diarrhoea—Etoposide—lung cancer	0.000335	0.00147	CcSEcCtD
Vilazodone—Eye disorder—Doxorubicin—lung cancer	0.000334	0.00147	CcSEcCtD
Vilazodone—Cardiac disorder—Doxorubicin—lung cancer	0.000332	0.00146	CcSEcCtD
Vilazodone—Diarrhoea—Paclitaxel—lung cancer	0.000329	0.00144	CcSEcCtD
Vilazodone—Dizziness—Etoposide—lung cancer	0.000324	0.00142	CcSEcCtD
Vilazodone—Dizziness—Paclitaxel—lung cancer	0.000318	0.00139	CcSEcCtD
Vilazodone—Nausea—Cisplatin—lung cancer	0.000318	0.00139	CcSEcCtD
Vilazodone—Mental disorder—Doxorubicin—lung cancer	0.000314	0.00138	CcSEcCtD
Vilazodone—Convulsion—Methotrexate—lung cancer	0.000312	0.00137	CcSEcCtD
Vilazodone—Vomiting—Etoposide—lung cancer	0.000312	0.00137	CcSEcCtD
Vilazodone—Malnutrition—Doxorubicin—lung cancer	0.000312	0.00137	CcSEcCtD
Vilazodone—Flatulence—Doxorubicin—lung cancer	0.000307	0.00135	CcSEcCtD
Vilazodone—Arthralgia—Methotrexate—lung cancer	0.000306	0.00134	CcSEcCtD
Vilazodone—Vomiting—Paclitaxel—lung cancer	0.000306	0.00134	CcSEcCtD
Vilazodone—Dysgeusia—Doxorubicin—lung cancer	0.000305	0.00134	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000304	0.00133	CcSEcCtD
Vilazodone—Nervousness—Doxorubicin—lung cancer	0.000303	0.00133	CcSEcCtD
Vilazodone—Vision blurred—Doxorubicin—lung cancer	0.000294	0.00129	CcSEcCtD
Vilazodone—Asthenia—Docetaxel—lung cancer	0.000292	0.00128	CcSEcCtD
Vilazodone—Nausea—Etoposide—lung cancer	0.000291	0.00128	CcSEcCtD
Vilazodone—Nervous system disorder—Methotrexate—lung cancer	0.000288	0.00126	CcSEcCtD
Vilazodone—Agitation—Doxorubicin—lung cancer	0.000286	0.00126	CcSEcCtD
Vilazodone—Nausea—Paclitaxel—lung cancer	0.000286	0.00125	CcSEcCtD
Vilazodone—Skin disorder—Methotrexate—lung cancer	0.000285	0.00125	CcSEcCtD
Vilazodone—Hyperhidrosis—Methotrexate—lung cancer	0.000284	0.00125	CcSEcCtD
Vilazodone—Diarrhoea—Docetaxel—lung cancer	0.000279	0.00122	CcSEcCtD
Vilazodone—Palpitations—Doxorubicin—lung cancer	0.000275	0.00121	CcSEcCtD
Vilazodone—Convulsion—Doxorubicin—lung cancer	0.00027	0.00118	CcSEcCtD
Vilazodone—Dizziness—Docetaxel—lung cancer	0.000269	0.00118	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000268	0.00117	CcSEcCtD
Vilazodone—Insomnia—Methotrexate—lung cancer	0.000266	0.00116	CcSEcCtD
Vilazodone—Arthralgia—Doxorubicin—lung cancer	0.000265	0.00116	CcSEcCtD
Vilazodone—Paraesthesia—Methotrexate—lung cancer	0.000264	0.00116	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000263	0.00116	CcSEcCtD
Vilazodone—Somnolence—Methotrexate—lung cancer	0.000261	0.00114	CcSEcCtD
Vilazodone—Dry mouth—Doxorubicin—lung cancer	0.000259	0.00114	CcSEcCtD
Vilazodone—Vomiting—Docetaxel—lung cancer	0.000259	0.00114	CcSEcCtD
Vilazodone—Dyspepsia—Methotrexate—lung cancer	0.000259	0.00113	CcSEcCtD
Vilazodone—Decreased appetite—Methotrexate—lung cancer	0.000255	0.00112	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Methotrexate—lung cancer	0.000254	0.00111	CcSEcCtD
Vilazodone—Fatigue—Methotrexate—lung cancer	0.000253	0.00111	CcSEcCtD
Vilazodone—Nervous system disorder—Doxorubicin—lung cancer	0.000249	0.00109	CcSEcCtD
Vilazodone—Skin disorder—Doxorubicin—lung cancer	0.000247	0.00108	CcSEcCtD
Vilazodone—Hyperhidrosis—Doxorubicin—lung cancer	0.000246	0.00108	CcSEcCtD
Vilazodone—Nausea—Docetaxel—lung cancer	0.000242	0.00106	CcSEcCtD
Vilazodone—Feeling abnormal—Methotrexate—lung cancer	0.000242	0.00106	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000232	0.00102	CcSEcCtD
Vilazodone—Insomnia—Doxorubicin—lung cancer	0.00023	0.00101	CcSEcCtD
Vilazodone—Paraesthesia—Doxorubicin—lung cancer	0.000228	0.001	CcSEcCtD
Vilazodone—Somnolence—Doxorubicin—lung cancer	0.000226	0.000991	CcSEcCtD
Vilazodone—Dyspepsia—Doxorubicin—lung cancer	0.000224	0.000982	CcSEcCtD
Vilazodone—Decreased appetite—Doxorubicin—lung cancer	0.000221	0.000969	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Doxorubicin—lung cancer	0.00022	0.000963	CcSEcCtD
Vilazodone—Fatigue—Doxorubicin—lung cancer	0.000219	0.000961	CcSEcCtD
Vilazodone—Asthenia—Methotrexate—lung cancer	0.000211	0.000924	CcSEcCtD
Vilazodone—Feeling abnormal—Doxorubicin—lung cancer	0.00021	0.000919	CcSEcCtD
Vilazodone—Diarrhoea—Methotrexate—lung cancer	0.000201	0.000881	CcSEcCtD
Vilazodone—Dizziness—Methotrexate—lung cancer	0.000194	0.000852	CcSEcCtD
Vilazodone—Vomiting—Methotrexate—lung cancer	0.000187	0.000819	CcSEcCtD
Vilazodone—Asthenia—Doxorubicin—lung cancer	0.000182	0.0008	CcSEcCtD
Vilazodone—Nausea—Methotrexate—lung cancer	0.000174	0.000765	CcSEcCtD
Vilazodone—Diarrhoea—Doxorubicin—lung cancer	0.000174	0.000763	CcSEcCtD
Vilazodone—Dizziness—Doxorubicin—lung cancer	0.000168	0.000737	CcSEcCtD
Vilazodone—Vomiting—Doxorubicin—lung cancer	0.000162	0.000709	CcSEcCtD
Vilazodone—Nausea—Doxorubicin—lung cancer	0.000151	0.000662	CcSEcCtD
Vilazodone—CYP2D6—Metabolism—GSTA2—lung cancer	3.57e-05	0.000214	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—JUNB—lung cancer	3.56e-05	0.000213	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—POMC—lung cancer	3.48e-05	0.000208	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ANXA1—lung cancer	3.48e-05	0.000208	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CKB—lung cancer	3.46e-05	0.000207	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CG—lung cancer	3.45e-05	0.000207	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTA1—lung cancer	3.45e-05	0.000206	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ABCC3—lung cancer	3.41e-05	0.000204	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CREBBP—lung cancer	3.39e-05	0.000203	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FLT1—lung cancer	3.37e-05	0.000202	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CD—lung cancer	3.34e-05	0.0002	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CG—lung cancer	3.34e-05	0.0002	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AKR1C1—lung cancer	3.3e-05	0.000198	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOTCH3—lung cancer	3.3e-05	0.000198	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APP—lung cancer	3.3e-05	0.000198	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—POMC—lung cancer	3.29e-05	0.000197	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGF9—lung cancer	3.27e-05	0.000196	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTM2—lung cancer	3.25e-05	0.000195	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CNDP2—lung cancer	3.25e-05	0.000195	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—STK11—lung cancer	3.23e-05	0.000194	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CD—lung cancer	3.22e-05	0.000193	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6R—lung cancer	3.21e-05	0.000192	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—UGT1A1—lung cancer	3.2e-05	0.000192	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—POMC—lung cancer	3.18e-05	0.00019	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ALB—lung cancer	3.17e-05	0.00019	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MTMR3—lung cancer	3.16e-05	0.000189	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—JUNB—lung cancer	3.12e-05	0.000187	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FOXO3—lung cancer	3.12e-05	0.000187	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GNG11—lung cancer	3.09e-05	0.000185	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PGAM1—lung cancer	3.08e-05	0.000185	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—MAP2K1—lung cancer	3.06e-05	0.000183	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CD—lung cancer	3.04e-05	0.000182	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CG—lung cancer	3.03e-05	0.000182	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALDOA—lung cancer	2.94e-05	0.000176	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2A7—lung cancer	2.94e-05	0.000176	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CD—lung cancer	2.94e-05	0.000176	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AVP—lung cancer	2.92e-05	0.000175	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CB—lung cancer	2.91e-05	0.000175	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—POMC—lung cancer	2.89e-05	0.000173	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SDC4—lung cancer	2.88e-05	0.000172	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NCOA3—lung cancer	2.86e-05	0.000171	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—STK11—lung cancer	2.84e-05	0.00017	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6R—lung cancer	2.82e-05	0.000169	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF1R—lung cancer	2.81e-05	0.000168	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CB—lung cancer	2.8e-05	0.000168	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCL8—lung cancer	2.8e-05	0.000168	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ABCG2—lung cancer	2.78e-05	0.000166	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ADCY1—lung cancer	2.78e-05	0.000166	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS2—lung cancer	2.78e-05	0.000166	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HES1—lung cancer	2.76e-05	0.000166	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FOXO3—lung cancer	2.74e-05	0.000164	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HPGDS—lung cancer	2.72e-05	0.000163	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ENO2—lung cancer	2.72e-05	0.000163	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—RAF1—lung cancer	2.71e-05	0.000162	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPP2R1B—lung cancer	2.71e-05	0.000162	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MAP2K1—lung cancer	2.68e-05	0.000161	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—IL2—lung cancer	2.68e-05	0.00016	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CD—lung cancer	2.67e-05	0.00016	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CB—lung cancer	2.65e-05	0.000159	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTT1—lung cancer	2.64e-05	0.000158	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA3—lung cancer	2.62e-05	0.000157	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—RRM1—lung cancer	2.62e-05	0.000157	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GCLC—lung cancer	2.61e-05	0.000156	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP2A6—lung cancer	2.61e-05	0.000156	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AVP—lung cancer	2.57e-05	0.000154	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CB—lung cancer	2.56e-05	0.000153	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL8—lung cancer	2.54e-05	0.000152	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB3—lung cancer	2.53e-05	0.000151	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ENO1—lung cancer	2.48e-05	0.000148	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1R—lung cancer	2.47e-05	0.000148	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—B4GALT5—lung cancer	2.46e-05	0.000148	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL8—lung cancer	2.46e-05	0.000147	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL2—lung cancer	2.43e-05	0.000146	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HES1—lung cancer	2.43e-05	0.000145	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TERT—lung cancer	2.42e-05	0.000145	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTEN—lung cancer	2.42e-05	0.000145	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA4—lung cancer	2.4e-05	0.000144	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—RAF1—lung cancer	2.38e-05	0.000143	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FGFR1—lung cancer	2.35e-05	0.000141	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—IL2—lung cancer	2.35e-05	0.000141	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA2—lung cancer	2.34e-05	0.00014	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CB—lung cancer	2.32e-05	0.000139	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HIF1A—lung cancer	2.32e-05	0.000139	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—EP300—lung cancer	2.31e-05	0.000138	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA1—lung cancer	2.25e-05	0.000135	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOA1—lung cancer	2.23e-05	0.000134	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCL8—lung cancer	2.23e-05	0.000134	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCC3—lung cancer	2.23e-05	0.000133	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP2E1—lung cancer	2.22e-05	0.000133	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB3—lung cancer	2.22e-05	0.000133	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KDR—lung cancer	2.21e-05	0.000133	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NQO1—lung cancer	2.2e-05	0.000132	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AKR1C1—lung cancer	2.16e-05	0.000129	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL2—lung cancer	2.13e-05	0.000128	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TERT—lung cancer	2.13e-05	0.000127	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—UGT1A1—lung cancer	2.09e-05	0.000125	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGFR1—lung cancer	2.06e-05	0.000124	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CG—lung cancer	2.04e-05	0.000122	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APC—lung cancer	2.04e-05	0.000122	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KIT—lung cancer	2.04e-05	0.000122	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—NRAS—lung cancer	2.04e-05	0.000122	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HIF1A—lung cancer	2.03e-05	0.000122	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GNG11—lung cancer	2.02e-05	0.000121	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGF—lung cancer	2.02e-05	0.000121	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—STK11—lung cancer	1.98e-05	0.000119	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOA1—lung cancer	1.96e-05	0.000118	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—MAPK3—lung cancer	1.95e-05	0.000117	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KDR—lung cancer	1.94e-05	0.000116	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—POMC—lung cancer	1.94e-05	0.000116	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALDOA—lung cancer	1.92e-05	0.000115	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—BRAF—lung cancer	1.92e-05	0.000115	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6R—lung cancer	1.89e-05	0.000113	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CREBBP—lung cancer	1.89e-05	0.000113	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOA3—lung cancer	1.87e-05	0.000112	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EGFR—lung cancer	1.86e-05	0.000111	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTP1—lung cancer	1.83e-05	0.00011	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCG2—lung cancer	1.82e-05	0.000109	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ADCY1—lung cancer	1.82e-05	0.000109	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAP2K1—lung cancer	1.81e-05	0.000108	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CD—lung cancer	1.79e-05	0.000107	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CG—lung cancer	1.79e-05	0.000107	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APC—lung cancer	1.79e-05	0.000107	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KIT—lung cancer	1.79e-05	0.000107	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—NRAS—lung cancer	1.79e-05	0.000107	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CAT—lung cancer	1.78e-05	0.000107	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HPGDS—lung cancer	1.78e-05	0.000107	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ENO2—lung cancer	1.78e-05	0.000107	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CA—lung cancer	1.78e-05	0.000106	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGF—lung cancer	1.77e-05	0.000106	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.77e-05	0.000106	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—KRAS—lung cancer	1.76e-05	0.000105	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ABCB1—lung cancer	1.73e-05	0.000104	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTT1—lung cancer	1.73e-05	0.000103	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MAPK3—lung cancer	1.72e-05	0.000103	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CA—lung cancer	1.71e-05	0.000102	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2A6—lung cancer	1.71e-05	0.000102	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GCLC—lung cancer	1.71e-05	0.000102	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—POMC—lung cancer	1.71e-05	0.000102	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TYMS—lung cancer	1.7e-05	0.000102	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—BRAF—lung cancer	1.68e-05	0.000101	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTM1—lung cancer	1.68e-05	0.000101	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6R—lung cancer	1.66e-05	9.96e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CREBBP—lung cancer	1.66e-05	9.95e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EGFR—lung cancer	1.63e-05	9.77e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ENO1—lung cancer	1.62e-05	9.7e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CA—lung cancer	1.61e-05	9.66e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MDM2—lung cancer	1.61e-05	9.62e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RAF1—lung cancer	1.6e-05	9.59e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1A1—lung cancer	1.6e-05	9.56e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAP2K1—lung cancer	1.59e-05	9.49e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB2—lung cancer	1.58e-05	9.49e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ERCC2—lung cancer	1.58e-05	9.48e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CD—lung cancer	1.57e-05	9.43e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MTOR—lung cancer	1.56e-05	9.36e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CB—lung cancer	1.56e-05	9.36e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CA—lung cancer	1.56e-05	9.34e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—KRAS—lung cancer	1.54e-05	9.23e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL8—lung cancer	1.5e-05	9e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—HRAS—lung cancer	1.49e-05	8.94e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2E1—lung cancer	1.45e-05	8.7e-05	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AKT1—lung cancer	1.45e-05	8.69e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CASP3—lung cancer	1.44e-05	8.61e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL2—lung cancer	1.44e-05	8.6e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NQO1—lung cancer	1.44e-05	8.6e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6—lung cancer	1.43e-05	8.56e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CA—lung cancer	1.42e-05	8.48e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MDM2—lung cancer	1.41e-05	8.45e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RAF1—lung cancer	1.41e-05	8.42e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCND1—lung cancer	1.4e-05	8.38e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—JUN—lung cancer	1.4e-05	8.37e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—AKT1—lung cancer	1.4e-05	8.36e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB2—lung cancer	1.39e-05	8.33e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CB—lung cancer	1.37e-05	8.22e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MTOR—lung cancer	1.37e-05	8.22e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOA1—lung cancer	1.37e-05	8.2e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP9—lung cancer	1.36e-05	8.14e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN1A—lung cancer	1.35e-05	8.11e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTEN—lung cancer	1.35e-05	8.09e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL8—lung cancer	1.32e-05	7.9e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AKT1—lung cancer	1.32e-05	7.89e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—HRAS—lung cancer	1.31e-05	7.85e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—STK11—lung cancer	1.29e-05	7.75e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EP300—lung cancer	1.29e-05	7.72e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AKT1—lung cancer	1.27e-05	7.63e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CASP3—lung cancer	1.26e-05	7.56e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL2—lung cancer	1.26e-05	7.55e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6—lung cancer	1.25e-05	7.51e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SRC—lung cancer	1.25e-05	7.5e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CG—lung cancer	1.25e-05	7.48e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCND1—lung cancer	1.23e-05	7.36e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—JUN—lung cancer	1.23e-05	7.34e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—VEGFA—lung cancer	1.22e-05	7.31e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—STAT3—lung cancer	1.21e-05	7.24e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NRAS—lung cancer	1.21e-05	7.22e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTP1—lung cancer	1.2e-05	7.17e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP9—lung cancer	1.19e-05	7.15e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—POMC—lung cancer	1.19e-05	7.12e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN1A—lung cancer	1.19e-05	7.12e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTEN—lung cancer	1.19e-05	7.1e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CAT—lung cancer	1.17e-05	6.98e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CREBBP—lung cancer	1.16e-05	6.94e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AKT1—lung cancer	1.16e-05	6.93e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAPK3—lung cancer	1.15e-05	6.91e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCB1—lung cancer	1.13e-05	6.79e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EP300—lung cancer	1.13e-05	6.77e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MYC—lung cancer	1.12e-05	6.72e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TYMS—lung cancer	1.11e-05	6.67e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTM1—lung cancer	1.1e-05	6.59e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SRC—lung cancer	1.1e-05	6.59e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CD—lung cancer	1.1e-05	6.58e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGFR—lung cancer	1.1e-05	6.58e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALB—lung cancer	1.08e-05	6.5e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VEGFA—lung cancer	1.07e-05	6.42e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—STAT3—lung cancer	1.06e-05	6.35e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NRAS—lung cancer	1.06e-05	6.34e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1A1—lung cancer	1.04e-05	6.25e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KRAS—lung cancer	1.04e-05	6.21e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ERCC2—lung cancer	1.03e-05	6.2e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAPK3—lung cancer	1.01e-05	6.07e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MYC—lung cancer	9.86e-06	5.9e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGFR—lung cancer	9.64e-06	5.77e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CB—lung cancer	9.58e-06	5.74e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CA—lung cancer	9.53e-06	5.71e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS2—lung cancer	9.49e-06	5.68e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TP53—lung cancer	9.22e-06	5.52e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KRAS—lung cancer	9.11e-06	5.45e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOA1—lung cancer	8.95e-06	5.36e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HRAS—lung cancer	8.82e-06	5.28e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6—lung cancer	8.44e-06	5.05e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CA—lung cancer	8.37e-06	5.01e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTEN—lung cancer	8.27e-06	4.96e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CG—lung cancer	8.17e-06	4.89e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TP53—lung cancer	8.1e-06	4.85e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—EP300—lung cancer	7.89e-06	4.73e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKT1—lung cancer	7.79e-06	4.66e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—POMC—lung cancer	7.78e-06	4.66e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HRAS—lung cancer	7.74e-06	4.64e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CREBBP—lung cancer	7.58e-06	4.54e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6—lung cancer	7.41e-06	4.44e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CD—lung cancer	7.18e-06	4.3e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALB—lung cancer	7.09e-06	4.25e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKT1—lung cancer	6.84e-06	4.09e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CB—lung cancer	6.26e-06	3.75e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS2—lung cancer	6.2e-06	3.72e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CA—lung cancer	5.84e-06	3.5e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTEN—lung cancer	5.41e-06	3.24e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—EP300—lung cancer	5.16e-06	3.09e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AKT1—lung cancer	4.77e-06	2.86e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CA—lung cancer	3.82e-06	2.29e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AKT1—lung cancer	3.12e-06	1.87e-05	CbGpPWpGaD
